| Topic | Faculty | |
|---|---|---|
| 12:45–12:48 | Welcome and introduction | Faiez Zannad (France) and John McMurray (UK) |
| 12:48–12:58 | One year after updating the heart failure guidelines – has the management of patients with HFrEF changed? | John McMurray (UK) |
| 12:58–13:28 | Managing contemporary HFrEF therapies – clinical case discussion | Peter van der Meer (The Netherlands) |
| 13:28–13:58 | Optimising contemporary HFrEF therapies in patients with comorbidities – clinical case discussion | Frank Ruschitzka (Switzerland) |
| 13:58–14:00 | Summary and key learning points | Faiez Zannad (France) |
The learning objectives for this open forum expert discussion focused on:
- Understand how the latest guidelines and clinical evidence impact clinical practice in the treatment of heart failure with reduced ejection fraction
- Understand the use of evidence-based treatments in different patient types with heart failure with reduced ejection fraction
- Appreciate the importance of patient follow-up to ensure optimal treatment management to achieve improved care
- Cardiologists
- Heart Failure Specialists
Novartis sponsored satellite symposium at Heart Failure 2017 & 4th World Congress on Acute Failure
©2017 Novartis Pharma AG, CH-4002 Basel – March 2017 – GLCM/HTF/0408
©2017 Novartis Pharma AG, CH-4002 Basel – March 2017 – GLCM/HTF/0408
